Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case.

Literature DB >> 35050748

Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case.

Samuel J Klempner¹, Andrew Hendifar², Kevin M Waters³, Nicholas Nissen⁴, Eric Vail³, Richard Tuli⁵, Alain Mita².

Abstract

Entities: Chemical

Year: 2020 PMID： 35050748 DOI： 10.1200/PO.20.00034

Source DB: PubMed Journal: JCO Precis Oncol ISSN： 2473-4284

Keyword Cloud
Cited

× No keyword cloud information.

3 in total

1. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.

Authors: Fangdi Sun; James P Grenert; Lisa Tan; Jessica Van Ziffle; Nancy M Joseph; Claire K Mulvey; Emily Bergsland
Journal: JCO Precis Oncol Date: 2022-06

2. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting.

Authors: Shumei Kato; Bing Li; Jacob J Adashek; Seong Won Cha; Daniella Bianchi-Frias; Dajun Qian; Lisa Kim; Tiffany W So; Marcus Mitchell; Naoki Kamei; Robert Hoiness; Jayne Hoo; Phillip N Gray; Teruaki Iyama; Masahide Kashiwagi; Hsiao-Mei Lu; Razelle Kurzrock
Journal: Oncoimmunology Date: 2022-03-29 Impact factor: 8.110

3. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O⁶-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.

Authors: Federica Morano; Alessandra Raimondi; Filippo Pagani; Sara Lonardi; Lisa Salvatore; Chiara Cremolini; Sabina Murgioni; Giovanni Randon; Federica Palermo; Lorenzo Antonuzzo; Nicoletta Pella; Patrizia Racca; Michele Prisciandaro; Monica Niger; Francesca Corti; Francesca Bergamo; Alberto Zaniboni; Margherita Ratti; Michele Palazzo; Celeste Cagnazzo; Maria Alessandra Calegari; Federica Marmorino; Iolanda Capone; Elena Conca; Adele Busico; Silvia Brich; Elena Tamborini; Federica Perrone; Massimo Di Maio; Massimo Milione; Maria Di Bartolomeo; Filippo de Braud; Filippo Pietrantonio
Journal: J Clin Oncol Date: 2022-03-08 Impact factor: 50.717

3 in total

Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case.

1. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.

2. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting.

3. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.

3. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O⁶-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.